ELTP
Elite Pharmaceuticals, Inc.
Price Chart
Latest Quote
$0.36
-0.01 (-2.70%)
Current Price
| Previous Close | $0.37 |
| Open | $0.37 |
| Day High | $0.37 |
| Day Low | $0.35 |
| Volume | 113,708 |
Stock Information
| Shares Outstanding | 1.08B |
| Total Debt | $6.06M |
| Cash Equivalents | $21.09M |
| Revenue | $140.12M |
| Net Income | $43.41M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $387.72M |
| P/E Ratio | 9.00 |
| EPS (TTM) | $0.04 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $382.23M |
| Sales | $140.12M |
| Income | $43.41M |
| Book/sh | $0.07 |
| Cash/sh | $0.02 |
| Employees | 68 |
Financial Ratios
| Quick Ratio | 5.28 |
| Current Ratio | 7.34 |
| Debt/Eq | 7.54 |
Returns & Margins
| ROA | 29.75% |
| ROE | 74.36% |
| Gross Margin | 51.06% |
| Operating Margin | 28.53% |
| Profit Margin | 30.98% |
Ownership
| Insider Ownership | 21.96% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 2.77 |
| P/B | 4.80 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.37 |
| SMA50 | $0.36 |
| SMA200 | $0.48 |
| RSI | 54.17 |
| ATR | 0.0329 |
| Shares Float | 835.88M |
| Short Ratio | 0.87 |
| Volatility | 0.38 |
| Rel Volume | 0.55 |
Performance History
| Week | +2.86% |
| Month | +2.86% |
| Quarter | -5.26% |
| 6 Months | -28.00% |
| YTD | -28.00% |
| Year | -53.25% |
| 3 Years | +1100.00% |
| 5 Years | +500.00% |
| 10 Years | +24.14% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.36 | 342,400 |
| 2026-06-17 | $0.37 | 352,600 |
| 2026-06-16 | $0.37 | 500,200 |
| 2026-06-15 | $0.37 | 694,700 |
| 2026-06-12 | $0.34 | 1,317,900 |
| 2026-06-11 | $0.35 | 746,900 |
| 2026-06-10 | $0.36 | 239,700 |
| 2026-06-09 | $0.36 | 451,800 |
| 2026-06-08 | $0.37 | 262,400 |
| 2026-06-05 | $0.39 | 721,900 |
| 2026-06-04 | $0.40 | 1,082,800 |
| 2026-06-03 | $0.44 | 1,086,900 |
| 2026-06-02 | $0.40 | 1,405,400 |
| 2026-06-01 | $0.36 | 1,348,400 |
| 2026-05-29 | $0.34 | 477,800 |
| 2026-05-28 | $0.35 | 279,800 |
| 2026-05-27 | $0.34 | 178,700 |
| 2026-05-26 | $0.35 | 351,000 |
| 2026-05-22 | $0.35 | 341,300 |
| 2026-05-21 | $0.34 | 293,500 |
| 2026-05-20 | $0.34 | 678,600 |
| 2026-05-19 | $0.35 | 270,400 |
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates through Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals segments. It owns, licenses, manufactures, and sales of generic, oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. In addition, the company provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with sequestered Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. Additionally, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
đ° Latest News
The Zacks Analyst Blog Highlights GE Aerospace, Shell, McKesson, Elite Pharmaceuticals and Geospace Technologies
Zacks âĸ 2026-03-18T14:23:00Z
Top Stock Reports for GE Aerospace, Shell & McKesson
Zacks âĸ 2026-03-17T20:10:00Z
Elite Pharmaceuticals Inc (ELTP) Q3 2026 Earnings Call Highlights: Record Revenue Surge and ...
GuruFocus.com âĸ 2026-02-24T01:00:48ZElite Pharmaceuticals Stock Dips Post Q3 Earnings Despite Revenue Jump
Zacks âĸ 2026-02-20T15:57:00Z
Elite Pharmaceuticals Q3 Earnings Call Highlights
MarketBeat âĸ 2026-02-19T05:07:43Z
ELTP Stock Declines Despite Solid Q2 Earnings and Revenue Performance
Zacks âĸ 2025-11-19T16:37:00Z
The Zacks Analyst Blog Highlights Berkshire Hathaway, Toyota Motor, McDonald's, Elite Pharmaceuticals and BK Technologies
Zacks âĸ 2025-08-28T08:36:00Z
Top Analyst Reports for Berkshire Hathaway, Toyota Motor & McDonald's
Zacks âĸ 2025-08-27T20:55:00Z
ELTP Stock Gains Following Q1 Earnings Showing Strong Revenue Growth
Zacks âĸ 2025-08-21T19:07:00Z
2 Outperform Rated Small Caps with Recent Pull-backs
Zacks âĸ 2025-08-11T20:53:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $43,523,360 | $30,129,946 | $17,479,862 | $17,226,993 |
| Cost Of Revenue | $43,957,274 | $30,268,025 | $17,561,093 | $17,466,763 |
| Total Revenue | $84,043,929 | $56,625,128 | $34,155,114 | $32,262,117 |
| Operating Revenue | $84,043,929 | $56,625,128 | $34,155,114 | $32,262,117 |
| Expenses | ||||
| Interest Expense | $772,367 | $588,622 | $1,112,707 | $191,816 |
| Total Expenses | $62,840,035 | $45,836,359 | $30,186,305 | $27,191,407 |
| Other Income Expense | $-20,504,611 | $-9,757,973 | $1,122,319 | $1,425,409 |
| Net Non Operating Interest Income Expense | $-751,423 | $-567,704 | $-1,105,254 | $-191,690 |
| Interest Expense Non Operating | $772,367 | $588,622 | $1,112,707 | $191,816 |
| Operating Expense | $18,882,761 | $15,568,334 | $12,625,212 | $9,724,644 |
| General And Administrative Expense | $9,229,495 | $7,305,035 | $5,161,597 | $4,478,356 |
| Other Non Operating Income Expenses | - | $-5,743,468 | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Net Interest Income | $-751,423 | $-567,704 | $-1,105,254 | $-191,690 |
| Interest Income | $20,944 | $20,918 | $7,453 | $126 |
| Normalized Income | $11,883,984 | $23,280,090 | $2,558,922 | $7,772,172 |
| Net Income From Continuing And Discontinued Operation | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Total Operating Income As Reported | $19,600,468 | $10,788,769 | $3,676,002 | $5,070,710 |
| Net Income Common Stockholders | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Net Income | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Net Income Including Noncontrolling Interests | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Net Income Continuous Operations | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Pretax Income | $-52,140 | $463,092 | $3,985,874 | $6,304,429 |
| Special Income Charges | $-1,603,426 | $1,761,792 | $707,193 | $0 |
| Interest Income Non Operating | $20,944 | $20,918 | $7,453 | $126 |
| Operating Income | $21,203,894 | $10,788,769 | $3,968,809 | $5,070,710 |
| Depreciation Amortization Depletion Income Statement | $1,688,429 | $1,379,948 | $1,263,452 | $1,194,939 |
| Depreciation And Amortization In Income Statement | $1,688,429 | $1,379,948 | $1,263,452 | $1,194,939 |
| Gross Profit | $40,086,655 | $26,357,103 | $16,594,021 | $14,795,354 |
| Earnings From Equity Interest Net Of Tax | - | - | $0 | $857,379 |
| Average Dilution Earnings | - | - | - | $-1,425,409 |
| Per Share | ||||
| Diluted EPS | $0.00 | $0.02 | $0.00 | $0.01 |
| Basic EPS | $0.00 | $0.02 | $0.00 | $0.01 |
| Other | ||||
| Tax Effect Of Unusual Items | $-4,305,968 | $-843,046 | $119,395 | $299,336 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $23,347,181 | $6,584,246 | $5,320,945 | $6,505,545 |
| Total Unusual Items | $-20,504,611 | $-4,014,505 | $1,122,319 | $1,425,409 |
| Total Unusual Items Excluding Goodwill | $-20,504,611 | $-4,014,505 | $1,122,319 | $1,425,409 |
| Reconciled Depreciation | $2,122,343 | $1,518,027 | $1,344,683 | $1,434,709 |
| EBITDA (Bullshit earnings) | $2,842,570 | $2,569,741 | $6,443,264 | $7,930,954 |
| EBIT | $720,227 | $1,051,714 | $5,098,581 | $6,496,245 |
| Diluted Average Shares | $1,068,290,368 | $1,023,225,623 | $1,012,911,346 | $1,010,607,713 |
| Basic Average Shares | $1,068,290,368 | $1,015,443,363 | $1,012,911,346 | $1,010,607,713 |
| Diluted NI Availto Com Stockholders | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Tax Provision | $4,262,519 | $-19,645,539 | $424,028 | $-1,736,437 |
| Impairment Of Capital Assets | $1,603,426 | $0 | $292,807 | $0 |
| Gain On Sale Of Security | $-18,901,185 | $-5,776,297 | $415,126 | $1,425,409 |
| Research And Development | $7,964,837 | $6,883,351 | $6,200,163 | $4,051,349 |
| Selling General And Administration | $9,229,495 | $7,305,035 | $5,161,597 | $4,478,356 |
| Other Gand A | $9,001,930 | $7,145,114 | $5,122,272 | $4,464,003 |
| Salaries And Wages | $227,565 | $159,921 | $39,325 | $14,353 |
| Gain On Sale Of Ppe | - | $0 | $1,000,000 | $0 |
| Other Special Charges | - | $-1,761,792 | - | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $47,877,227 | $51,241,590 | $22,619,032 | $18,587,992 |
| Total Assets | $96,387,477 | $83,653,536 | $40,896,018 | $35,148,898 |
| Total Non Current Assets | $38,648,330 | $43,639,347 | $19,385,721 | $16,287,509 |
| Other Non Current Assets | $453,776 | $432,832 | $412,434 | $405,039 |
| Non Current Prepaid Assets | $91,981 | $94,240 | $21,018 | $91,738 |
| Non Current Deferred Assets | $18,365,748 | $22,160,895 | $2,171,821 | $2,171,821 |
| Non Current Deferred Taxes Assets | $18,365,748 | $22,160,895 | $2,171,821 | $2,171,821 |
| Goodwill And Other Intangible Assets | $5,637,802 | $6,341,228 | $6,341,228 | $6,634,035 |
| Other Intangible Assets | $5,637,802 | $6,341,228 | $6,341,228 | $6,634,035 |
| Current Assets | $57,739,147 | $40,014,189 | $21,510,297 | $18,861,389 |
| Other Current Assets | $976,358 | $524,162 | $1,032,785 | $526,949 |
| Inventory | $16,240,376 | $12,930,464 | $9,550,716 | $6,741,170 |
| Receivables | $29,207,028 | $19,453,301 | $3,094,549 | $3,057,913 |
| Accounts Receivable | $29,207,028 | $19,453,301 | $3,094,549 | $3,057,913 |
| Allowance For Doubtful Accounts Receivable | $-387,533 | $-236,275 | $0 | $0 |
| Gross Accounts Receivable | $29,594,561 | $19,689,576 | $3,094,549 | $3,057,913 |
| Cash Cash Equivalents And Short Term Investments | $11,315,385 | $7,106,262 | $7,832,247 | $8,535,357 |
| Cash And Cash Equivalents | $11,315,385 | $7,106,262 | $7,832,247 | $8,535,357 |
| Cash Financial | $11,315,385 | $7,106,262 | $7,832,247 | $8,535,357 |
| Prepaid Assets | - | - | $1,032,785 | $526,949 |
| Debt | ||||
| Total Debt | $10,914,888 | $11,737,768 | $3,887,288 | $2,781,568 |
| Long Term Debt And Capital Lease Obligation | $5,832,820 | $6,717,390 | $3,561,520 | $2,224,787 |
| Long Term Debt | $3,033,124 | $3,279,690 | $3,561,520 | $1,388,894 |
| Current Debt And Capital Lease Obligation | $5,082,068 | $5,020,378 | $325,768 | $556,781 |
| Current Debt | $4,246,566 | $4,296,221 | $310,854 | $353,828 |
| Other Current Borrowings | $4,246,566 | $4,296,221 | $310,854 | $353,828 |
| Net Debt | - | $469,649 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $42,872,448 | $26,070,718 | $11,935,758 | $9,926,871 |
| Total Non Current Liabilities Net Minority Interest | $31,032,013 | $13,020,954 | $4,102,121 | $3,232,630 |
| Derivative Product Liabilities | $25,199,193 | $6,298,008 | $521,711 | $936,837 |
| Non Current Deferred Liabilities | $0 | $5,556 | $18,890 | $32,226 |
| Current Liabilities | $11,840,435 | $13,049,764 | $7,833,637 | $6,694,241 |
| Current Deferred Liabilities | $5,556 | $13,333 | $13,333 | $13,333 |
| Payables And Accrued Expenses | $6,630,926 | $7,809,828 | $7,494,536 | $5,981,127 |
| Interest Payable | $100,000 | $90,000 | - | - |
| Payables | $6,088,063 | $6,884,220 | $6,986,799 | $5,470,974 |
| Other Payable | $172,655 | - | $4,125,000 | $3,625,000 |
| Dividends Payable | $2,617,210 | $3,684,587 | $0 | - |
| Total Tax Payable | $340,614 | $485,327 | $414,989 | $414,989 |
| Income Tax Payable | $340,614 | $485,327 | $414,989 | $414,989 |
| Accounts Payable | $2,957,584 | $2,714,306 | $2,446,810 | $1,430,985 |
| Other Non Current Liabilities | - | - | - | $38,780 |
| Current Notes Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $53,515,029 | $57,582,818 | $28,960,260 | $25,222,027 |
| Total Equity Gross Minority Interest | $53,515,029 | $57,582,818 | $28,960,260 | $25,222,027 |
| Stockholders Equity | $53,515,029 | $57,582,818 | $28,960,260 | $25,222,027 |
| Retained Earnings | $-120,703,926 | $-116,389,267 | $-136,497,898 | $-140,059,744 |
| Other | ||||
| Treasury Shares Number | $100,000 | $100,000 | $100,000 | $100,000 |
| Ordinary Shares Number | $1,068,363,108 | $1,068,273,108 | $1,013,915,081 | $1,011,281,988 |
| Share Issued | $1,068,463,108 | $1,068,373,108 | $1,014,015,081 | $1,011,381,988 |
| Tangible Book Value | $47,877,227 | $51,241,590 | $22,619,032 | $18,587,992 |
| Invested Capital | $60,794,719 | $65,158,729 | $32,832,634 | $26,964,749 |
| Working Capital | $45,898,712 | $26,964,425 | $13,676,660 | $12,167,148 |
| Capital Lease Obligations | $3,635,198 | $4,161,857 | $14,914 | $1,038,846 |
| Total Capitalization | $56,548,153 | $60,862,508 | $32,521,780 | $26,610,921 |
| Treasury Stock | $306,841 | $306,841 | $306,841 | $306,841 |
| Additional Paid In Capital | $173,457,329 | $173,210,549 | $164,750,980 | $164,577,227 |
| Capital Stock | $1,068,467 | $1,068,377 | $1,014,019 | $1,011,385 |
| Common Stock | $1,068,467 | $1,068,377 | $1,014,019 | $1,011,385 |
| Non Current Deferred Revenue | $0 | $5,556 | $18,890 | $32,226 |
| Long Term Capital Lease Obligation | $2,799,696 | $3,437,700 | $0 | $835,893 |
| Current Deferred Revenue | $5,556 | $13,333 | $13,333 | $13,333 |
| Current Capital Lease Obligation | $835,502 | $724,157 | $14,914 | $202,953 |
| Pensionand Other Post Retirement Benefit Plans Current | $121,885 | $206,225 | $0 | $143,000 |
| Current Accrued Expenses | $542,863 | $925,608 | $507,737 | $510,153 |
| Net PPE | $14,099,023 | $14,610,152 | $10,439,220 | $6,984,876 |
| Accumulated Depreciation | $-17,028,700 | $-15,906,853 | $-14,586,335 | $-13,348,565 |
| Gross PPE | $31,127,723 | $30,517,005 | $25,025,555 | $20,333,441 |
| Other Properties | $3,771,778 | $4,434,859 | $13,062 | $1,031,884 |
| Machinery Furniture Equipment | $930,019 | $930,019 | $879,800 | $827,302 |
| Buildings And Improvements | $14,776,008 | $14,090,978 | $13,364,512 | $13,017,731 |
| Land And Improvements | $11,649,918 | $11,061,149 | $10,768,181 | $5,456,524 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $4,816,458 | $4,465,970 | $2,352,330 | $159,808 |
| Work In Process | $1,422,005 | $1,804,426 | $1,791,311 | $1,203,204 |
| Raw Materials | $10,001,913 | $6,660,068 | $5,407,075 | $5,378,158 |
| Dueto Related Parties Current | - | - | $70,000 | $90,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $4,930,557 | $-4,044,768 | $-2,397,914 | $6,009,748 |
| Operating Activities | ||||
| Operating Cash Flow | $7,455,639 | $-3,235,115 | $3,338,704 | $6,508,314 |
| Cash Flow From Continuing Operating Activities | $7,455,639 | $-3,235,115 | $3,338,704 | $6,508,314 |
| Operating Gains Losses | $19,022,666 | $5,776,297 | $-415,126 | $-1,425,409 |
| Investing Activities | ||||
| Capital Expenditure | $-2,525,082 | $-809,653 | $-5,736,618 | $-498,566 |
| Investing Cash Flow | $-2,399,832 | $-809,653 | $-5,736,618 | $-498,566 |
| Cash Flow From Continuing Investing Activities | $-2,399,832 | $-809,653 | $-5,736,618 | $-498,566 |
| Financing Activities | ||||
| Financing Cash Flow | $-825,740 | $3,339,181 | $1,702,199 | $-667,133 |
| Cash Flow From Continuing Financing Activities | $-825,740 | $3,339,181 | $1,702,199 | $-667,133 |
| Net Other Financing Charges | - | $46,443 | - | - |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-845,045 | $-660,819 | $-12,736,786 | $-667,133 |
| Issuance Of Debt | $0 | $4,000,000 | $14,438,985 | $0 |
| Interest Paid Supplemental Data | $672,409 | $119,412 | $1,098,537 | $177,636 |
| Income Tax Paid Supplemental Data | $612,085 | $292,000 | $424,028 | $0 |
| End Cash Position | $11,769,161 | $7,539,094 | $8,244,681 | $8,940,396 |
| Beginning Cash Position | $7,539,094 | $8,244,681 | $8,940,396 | $3,597,781 |
| Changes In Cash | $4,230,067 | $-705,587 | $-695,715 | $5,342,615 |
| Proceeds From Stock Option Exercised | $19,305 | $0 | - | - |
| Net Issuance Payments Of Debt | $-845,045 | $3,339,181 | $1,702,199 | $-667,133 |
| Net Long Term Debt Issuance | $-845,045 | $3,339,181 | $1,702,199 | $-667,133 |
| Long Term Debt Payments | $-845,045 | $-660,819 | $-12,736,786 | $-667,133 |
| Long Term Debt Issuance | $0 | $4,000,000 | $14,438,985 | $0 |
| Net Intangibles Purchase And Sale | $-900,000 | $0 | - | - |
| Purchase Of Intangibles | $-900,000 | $0 | - | - |
| Net PPE Purchase And Sale | $-1,499,832 | $-809,653 | $-5,736,618 | $-498,566 |
| Sale Of PPE | $125,250 | $0 | - | $0 |
| Purchase Of PPE | $-1,625,082 | $-809,653 | $-5,736,618 | $-498,566 |
| Change In Working Capital | $-15,166,285 | $-11,893,939 | $-2,012,298 | $-1,010,037 |
| Change In Other Working Capital | $-13,333 | $-13,334 | $-13,336 | $-13,332 |
| Change In Other Current Liabilities | $-423,333 | $-139,318 | $-67,566 | $-230,910 |
| Change In Payables And Accrued Expense | $-1,263,242 | $7,798,088 | $1,336,566 | $314,214 |
| Change In Accrued Expense | $-1,506,520 | $7,776,407 | $0 | - |
| Change In Interest Payable | $0 | $17,126 | $0 | - |
| Change In Payable | $243,278 | $21,681 | $1,336,566 | $314,214 |
| Change In Account Payable | $243,278 | $21,681 | $1,336,566 | $314,214 |
| Change In Prepaid Assets | $-251,480 | $435,401 | $-435,116 | $209,796 |
| Change In Inventory | $-3,309,912 | $-3,379,748 | $-2,809,546 | $-1,728,268 |
| Change In Receivables | $-9,904,985 | $-16,595,028 | $-36,636 | $438,463 |
| Changes In Account Receivables | $-9,904,985 | $-16,595,028 | $-36,636 | $438,463 |
| Other Non Cash Items | $14,178 | $-7,505,260 | $-12,533 | $1,152 |
| Stock Based Compensation | $227,565 | $8,513,927 | $579,325 | $781,475 |
| Provisionand Write Offof Assets | $151,258 | $236,276 | $0 | - |
| Asset Impairment Charge | $1,603,426 | $0 | $292,807 | $0 |
| Deferred Tax | $3,795,147 | $-19,989,074 | $0 | $-2,171,821 |
| Deferred Income Tax | $3,795,147 | $-19,989,074 | $0 | $-2,171,821 |
| Depreciation Amortization Depletion | $2,122,343 | $1,518,027 | $1,344,683 | $1,434,709 |
| Depreciation And Amortization | $2,122,343 | $1,518,027 | $1,344,683 | $1,434,709 |
| Depreciation | $2,122,343 | $1,518,027 | $1,344,683 | $1,434,709 |
| Gain Loss On Investment Securities | $18,901,185 | $5,776,297 | $-415,126 | $-1,425,409 |
| Net Income From Continuing Operations | $-4,314,659 | $20,108,631 | $3,561,846 | $8,898,245 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
Fetched: 2026-02-02